Trial Profile
A Randomized, Open-label Phase II/III Efficacy and Safety Study of Atezolizumab in Combination With FLOT Versus FLOT Alone in Patients With Gastric Cancer and Adenocarcinoma of the Oesophago-gastric Junction and High Immune Responsiveness (MO30039/MO43340) - The DANTE Trial
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 19 Dec 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Docetaxel; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Biomarker; Therapeutic Use
- Acronyms DANTE
- 14 Nov 2023 Interim Results (n=295) of the phase II proportion, focusing on surgical pathology and safety outcomes on an exploratory basis, published in the Journal of Clinical Oncology
- 08 Aug 2023 Planned number of patients changed from 559 to 674.
- 08 Aug 2023 Planned End Date changed from 15 Oct 2025 to 31 Dec 2027.